Local recurrence after curative resection for rectal carcinoma
The role of surgical resection

Jung-A Yun (MD)a, Jung Wook Huh (MD, PhD)b, c, Hee Cheol Kim (MD, PhD)b, c, Yoon Ah Park (MD)b, Yong Beom Cho (MD, PhD)b, Seong Hyeon Yun (MD, PhD)b, Woo Yong Lee (MD, PhD)b, Ho-Kyung Chun (MD, PhD)c
School of Medicine, Seoul, Korea. b College of Medicine, Guri, Korea. c Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, and Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University a Department of Surgery, Hanyang University Guri Hospital, Hanyang University

Supplemental Digital Content is available for this article.

Abstract
Local recurrence of rectal cancer is difficult to treat, may cause severe and disabling symptoms, and usually has a fatal outcome. The aim of this study was to document the clinical nature of locally recurrent rectal cancer and to determine the effect of surgical resection on long-term survival.

A retrospective review was conducted of the prospectively collected medical records of 2485 patients with primary rectal adenocarcinoma who underwent radical resection between September 1994 and December 2008. In total, 147 (5.9%) patients exhibited local recurrence. The most common type of local recurrence was lateral recurrence, whereas anastomotic recurrence was the most common type in patients without preoperative concurrent chemoradiotherapy (CCRT). Tumor location with respect to the anal verge significantly affected the local recurrence rate \( P < 0.001 \), whereas preoperative CCRT did not affect the local recurrence rate \( P = 0.433 \). Predictive factors for surgical resection of recurrent rectal cancer included less advanced tumor stage \( P = 0.017 \), RR = 3.840, 95% CI = 1.271–11.597), axial recurrence \( P < 0.001 \), RR = 5.772, 95% CI = 2.281–14.609), and isolated local recurrence \( P = 0.006 \), RR = 8.679, 95% CI = 1.846–40.815). Overall survival after diagnosis of local recurrence was negatively influenced by advanced pathologic tumor stage \( P = 0.040 \), RR = 1.867, 95% CI = 1.028–3.389), positive CRM \( P = 0.001 \), RR = 12.999, 95% CI = 2.906–57.604), combined distant metastases \( P = 0.001 \), RR = 2.086, 95% CI = 1.352–3.218), and nonsurgical resection of recurrent tumor \( P < 0.001 \), RR = 4.865, 95% CI = 2.586–9.153).

In conclusion, the clinical outcomes of local recurrence after curative resection of rectal cancer are diverse. Surgical resection of locally recurrent rectal cancer should be considered as an initial treatment, especially in patients with less advanced tumors and axial recurrence.

Abbreviations: CCRT = concurrent chemoradiotherapy, CEA = carcinoembryonic antigen, CRM = circumferential resection margin, CT = computed tomography, MRI = magnetic resonance imaging, PET = positron emission tomography, TME = total mesorectal excision.

Keywords: clinical course, local recurrence, prognosis, rectal cancer, surgical resection

1. Introduction
In patients with curatively resected rectal cancer, local recurrence is often difficult to treat, may cause severely disabling symptoms, and usually has a fatal outcome. Thus, previous studies have focused on identifying risk factors for local recurrence or on preventing local recurrence. In particular, considerable effort has been invested in treating patients with rectal cancer through advanced surgical techniques, adjuvant therapy, and neoadjuvant treatment. Heald et al[1] Heald and Ryal[2] standardized a novel total mesorectal excision (TME) approach for treating rectal cancer, whereas other groups have developed neoadjuvant treatment modalities that have further improved local control. After these types of treatment, the local recurrence rate has been reported to be 2.4% to 5.6% in various clinical trials.[3–5] Other studies on the clinical course, optimal treatment and prognosis of patients with local recurrence have also been...

Editor: Mahmoud Mohamed Abdelwahab Ali.

Authorship: J-AY collected and analyzed the data and wrote the manuscript. JWH and HCK designed and proposed the study, analyzed the data, performed the final revision of the manuscript, and are corresponding authors. YAP, YBC, SHY, WYL, and H-KC enrolled patients. All authors approved the final version of the manuscript.

Funding: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant number 2015R1A1A1A05001160). The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

*Department of Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea. bDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, cDepartment of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-No Derivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Medicine (2016) 95:27(e3942) Received: 27 December 2015 / Received in final form: 17 May 2016 / Accepted: 24 May 2016 http://dx.doi.org/10.1097/MD.0000000000003942
performed. Treatment failure patterns after management of recurrent rectal cancer have been reviewed elsewhere.\(^\text{[10]}\)

Some authors have reported survival benefit and long-term preservation of quality of life after curative resection of local recurrence\(^\text{[2]}\); however, such resection is possible only in approximately one-third of all recurrent tumors.\(^\text{[9]}\) Moreover, achievement of an optimal resection margin is technically challenging, even though advanced combined adjuvant and neoadjuvant chemoradiation modalities have been developed.\(^\text{[9]}\)

Another challenge for patients who undergo radical surgery for recurrent rectal cancer is the risk of synchronous distant metastasis. The combination of local and distant recurrences reduces not only the opportunity for curative resection, but also the potential radiotherapies that are available for local control. Therefore, obtaining information regarding recurrence patterns, natural course, associated risk factors, and treatment outcomes is extremely important. This knowledge will help improve oncologic outcomes and identify optimal care strategies for patients with recurrent rectal cancer.

The purpose of this study was therefore to document the clinical course and prognosis of local recurrence after curative resection for rectal adenocarcinoma and to identify the effect of surgical resection on long-term survival. This study also aimed to identify factors that affect patient prognosis after local recurrence.

2. Patients and methods

2.1. Patient selection and follow-up

From September 1994 to December 2008, 2485 patients underwent TME for primary rectal adenocarcinoma (tumor location: <15 cm from anal verge by rigid sigmoidoscopy or digital rectal examination),\(^\text{[10]}\) either with or without preoperative concurrent chemoradiotherapy (CCRT). The exclusion criteria were as follows: (1) hereditary colorectal cancer, (2) combined synchronous colorectal cancer, (3) combined other primary malignancy, (4) distant metastasis at the time of diagnosis. Among these 2485 patients, 435 were diagnosed with an isolated distant metastasis without local recurrence during the follow-up period; thus, 2050 patients were ultimately included in the analysis.

Among these 2050 patients, 356 (17.4%) underwent preoperative CCRT. The indication for preoperative CCRT in our institution was T3 or T4 rectal cancer or suspected perirectal lymph node metastases based on radiologic imaging studies. All patients underwent preoperative therapy performed according to the same protocol. Radiation therapy was administered using a 3-field technique; doses of 40.4 to 50.4 Gy were delivered. Chemotherapy was delivered concurrently using 2 chemotherapeutic regimens: (1) 5-fluorouracil (500 mg/m² per day) for 3 days during the first and last weeks of radiotherapy; and (2) oral capecitabine (825 mg/m²) twice daily during radiotherapy without weekend breaks. In principle, surgery was performed 6 to 8 weeks after the completion of preoperative therapy.

The Institutional Review Board at Samsung Medical Center approved this study. Clinicopathologic information was obtained through comprehensive chart review, and follow-up data were obtained from patient medical records and the National Bureau of Statistics. A circumferential resection margin (CRM) ≤ 1 mm was scored as a negative resection margin based on results from a recent study at our institution.\(^\text{[11]}\) The primary outcome measured in this analysis was local recurrence, and all patients were clinically evaluated for both local and distant recurrence during the follow-up period. Surveillance for recurrence was comprised of a physical examination, measurement of the serum carcinoembryonic antigen (CEA) level, colonoscopy, chest computed tomography (CT), and an abdomen-pelvis CT scan. These procedures were performed every 6 months for 3 years and annually thereafter. Other examinations, such as magnetic

| Table 1: Patient demographics (n = 2050). |
|-----------------------------------------|
|                                       |
| No recurrence                         |
|                                        |
| Local recurrence                      |
|                                        |
|                                       |
| Sex, n (%)                            |
|                                        |
| 754 (39.6)                            |
| 63 (42.9)                             |
| 0.440                                 |
|                                       |
| Female                                |
|                                        |
| 1149 (60.4)                           |
| 84 (57.1)                             |
|                                       |
| Male                                  |
|                                        |
|                                       |
| Age, y                                |
|                                        |
| Median, range                         |
|                                        |
| 59 (22–89)                            |
| 58 (22–87)                            |
| 0.346                                 |
|                                       |
| ≥60                                   |
|                                        |
| 906 (47.6)                            |
| 66 (44.9)                             |
| 0.526                                 |
|                                       |
| ASA                                   |
|                                        |
| 1–2                                   |
|                                        |
| 1831 (96.2)                           |
| 143 (97.3)                            |
| 0.511                                 |
|                                       |
| 3–4                                   |
|                                        |
| 72 (3.8)                              |
| 4 (2.7)                               |
|                                       |
| Distance from the anal verge, cm      |
|                                        |
| Median, range                         |
|                                        |
| 7.0 (1.0–15.0)                        |
| 5.0 (1.0–14.0)                        |
| <0.001                                |
|                                       |
| DRM, cm                               |
|                                        |
| Median, range                         |
|                                        |
| 2.0 (0.1–9.0)                         |
| 2.0 (0.1–7.0)                         |
| 0.760                                 |
|                                       |
| CRM                                   |
|                                        |
| Negative                               |
|                                        |
| 1207 (63.4)                           |
| 90 (61.2)                             |
| 0.323                                 |
|                                       |
| Positive                               |
|                                        |
| 16 (0.8)                              |
| 3 (2.0)                               |
|                                       |
| Not checked                            |
|                                        |
| 680 (35.7)                            |
| 54 (36.7)                             |
|                                       |
| Pathologic T stage                    |
|                                        |
| T2–2                                  |
|                                        |
| 729 (38.3)                            |
| 27 (18.4)                             |
| <0.001                                |
|                                       |
| T3–4                                  |
|                                        |
| 1174 (61.7)                           |
| 120 (81.6)                            |
|                                       |
| Pathologic N stage                    |
|                                        |
| N0                                    |
|                                        |
| 1243 (65.3)                           |
| 62 (42.2)                             |
| <0.001                                |
|                                       |
| N1–2                                  |
|                                        |
| 660 (34.7)                            |
| 85 (57.8)                             |
|                                       |
| Number of harvested lymph node        |
|                                        |
| Median, range                         |
|                                        |
| 15 (1–62)                             |
| 14 (1–45)                             |
| 0.334                                 |
|                                       |
| Surgical procedure                    |
|                                        |
| Sphincter-preserving resection         |
|                                        |
| 1615 (84.9)                           |
| 108 (73.5)                            |
| <0.001                                |
|                                       |
| Non-sphincter-preserving resection     |
|                                        |
| 298 (15.1)                            |
| 39 (26.5)                             |
|                                       |
| Initial CEA, ng/mL                    |
|                                        |
| ≤5                                    |
|                                        |
| 1282 (67.4)                           |
| 74 (50.3)                             |
| <0.001                                |
|                                       |
| >5                                    |
|                                        |
| 365 (19.2)                            |
| 41 (27.9)                             |
|                                       |
| Not available                         |
|                                        |
| 256 (13.5)                            |
| 32 (21.8)                             |
|                                       |
| Cell type                             |
|                                        |
| WD=MD                                 |
|                                        |
| 1781 (93.6)                           |
| 127 (86.4)                            |
| 0.001                                 |
|                                       |
| PD=MD+SRC                             |
|                                        |
| 122 (6.4)                             |
| 20 (13.6)                             |
|                                       |
| LVI                                   |
|                                        |
| No                                    |
|                                        |
| 875 (46.0)                            |
| 38 (25.9)                             |
| <0.001                                |
|                                       |
| Yes                                   |
|                                        |
| 317 (16.7)                            |
| 48 (32.7)                             |
|                                       |
| Not checked                           |
|                                        |
| 711 (37.4)                            |
| 61 (41.5)                             |
|                                       |
| PNI                                   |
|                                        |
| No                                    |
|                                        |
| 806 (42.4)                            |
| 45 (30.6)                             |
| <0.001                                |
|                                       |
| Yes                                   |
|                                        |
| 76 (4.0)                              |
| 20 (13.6)                             |
|                                       |
| Not checked                           |
|                                        |
| 1021 (53.7)                           |
| 82 (55.8)                             |
| 0.433                                 |
|                                       |
| Neoadjuvant CCRT                      |
|                                        |
| No                                    |
|                                        |
| 1576 (82.8)                           |
| 118 (80.3)                            |
| 0.012                                 |
|                                       |
| Yes                                   |
|                                        |
| 327 (17.2)                            |
| 29 (19.7)                             |
|                                       |
| Adjuvant chemotherapy/CCRT            |
|                                        |
| No                                    |
|                                        |
| 673 (35.4)                            |
| 37 (25.2)                             |
| 0.110                                 |
|                                       |
| Yes                                   |
|                                        |
| 1230 (64.6)                           |
| 110 (74.8)                            |

ASA=American Society of Anesthesiologists, CCRT=concurrent chemoradiotherapy, CEA=carcinoembryonic antigen, CRM=circumferential resection margin, DRM=distal resection margin, LVI=lymphovascular invasion, MD=moderately differentiated, MUC=mucinous, N=node, PD=poorly differentiated, PNI=perineural invasion, SRC=signet ring cell, T=tumor, WD=well differentiated.
Table 2
Clinicopathologic features of patients according to preoperative CCRT (n = 2050).

|                              | Preoperative CCRT (−) (n = 1694) | Preoperative CCRT (+) (n = 356) | P      |
|------------------------------|---------------------------------|---------------------------------|--------|
|                              | No recurrence (n = 1576)        | Local recurrence (n = 118)      |        |
| Sex, n (%)                   | 653 (41.4)                     | 52 (44.1)                       | 0.576  |
| Female                       | 923 (58.6)                     | 66 (55.9)                       | 0.434  |
| Male                         | 62 (3.9)                       | 4 (3.4)                         |        |
| Age, y                       | 59 (24–89)                     | 58 (22–87)                      | 0.330  |
| Median, range                | 1514 (96.1)                    | 114 (96.6)                      | 1.000  |
| ASA                          | 1                               |                                 |        |
| 1–2                          | 13 (0.8)                       | 2 (1.7)                         |        |
| 3–4                          | 593 (37.6)                     | 44 (37.3)                       |        |
| Distance from anal verge, cm | 7.0 (0.0–15.0)                 | 5.0 (0.0–14.0)                  | <0.001 |
| Pathologic T stage           |                                 |                                 |        |
| (y)pT0–2                     | 548 (34.8)                     | 19 (16.1)                       |        |
| (y)pT3–4                     | 1028 (65.2)                    | 99 (83.9)                       |        |
| Pathologic N stage           |                                 |                                 |        |
| (y)pN0                        | 989 (62.8)                     | 44 (37.3)                       | <0.001 |
| (y)pN1–2                     | 587 (37.2)                     | 74 (62.7)                       |        |
| Number of harvested lymph node | 16 (1–62)                     | 15 (2–45)                       | 0.300  |
| Surgical procedure           | 1344 (85.3)                    | 87 (73.7)                       |        |
| Sphincter-preserving resection | 232 (14.7)                    | 31 (26.3)                       | <0.001 |
| Initial CEA, ng/mL           |                                 |                                 |        |
| <5                           | 1085 (68.8)                    | 56 (47.5)                       |        |
| >5                           | 294 (18.7)                     | 36 (30.5)                       |        |
| Not available                | 197 (12.5)                     | 26 (22.0)                       |        |
| Cell type                    |                                 |                                 | 0.002  |
| WD+MD                        | 1489 (94.5)                    | 103 (87.3)                      | 0.350  |
| PD+MUC+SRC                   | 87 (5.5)                       | 15 (12.7)                       |        |
| LVI                          |                                 |                                 | 0.001  |
| No                           | 668 (42.4)                     | 27 (22.9)                       |        |
| Yes                          | 293 (18.6)                     | 40 (33.9)                       |        |
| Not available                | 615 (39.0)                     | 51 (43.2)                       |        |
| Adjuvant chemotherapy        |                                 |                                 | 0.011  |
| No                           | 627 (39.8)                     | 31 (26.3)                       |        |
| Yes                          | 61 (3.9)                       | 17 (14.4)                       |        |
| Not available                | 888 (56.3)                     | 70 (59.3)                       |        |
| Adjuvant radiotherapy        |                                 |                                 | 0.024  |
| No                           | 850 (53.9)                     | 51 (43.2)                       |        |
| Yes                          | 726 (46.1)                     | 67 (56.8)                       |        |
| Pattern of recurrence        |                                 |                                 | 0.019* |
| Site of local recurrence     |                                 |                                 | 0.335* |
| Anterior                     | 5 (4.2)                        | 2 (6.9)                         |        |
| Posterior                    | 21 (17.8)                      | 8 (27.6)                        |        |
| Lateral                      | 41 (34.7)                      | 11 (37.9)                       |        |
| Anastomotic                  | 43 (36.4)                      | 5 (17.2)                        |        |
| Perineal                     | 8 (6.8)                        | 3 (10.3)                        |        |

* Calculated between CCRT(−) and CCRT(+) in patients with local recurrence.

ASA = American Society of Anesthesiologists, CCRT = concurrent chemoradiotherapy, CEA = carcinoembryonic antigen, CRM = circumferential resection margin, DRM = distal resection margin, LVI = lymphovascular invasion, MD = moderately differentiated, MUC = mucinous, N = node, PD = poorly differentiated, PNI = perineural invasion, SRC = signet ring cell, T = tumor, WD = well differentiated.
recurrence in the small pelvis.\textsuperscript{12} Recurrence location was classified into 1 of the following 5 subsites: presacral, anterior, anastomotic, lateral, and perineal.\textsuperscript{15} Anastomotic and perineal recurrence were considered as axial and the rest were considered nonaxial recurrence in further analyses.

### 2.2. Statistical analysis

Data were analyzed using SPSS software, version 18.0 (SPSS Inc, Chicago, IL). The significance of differences between 2 groups was analyzed using Student’s \( t \) test or Fisher’s exact test. Continuous data were recorded as means and ranges (minimum to maximum). Variables with \( P \) values < 0.05 according to univariate analysis were further analyzed using the Cox regression method for multivariate analysis. The disease-free survival of patients was examined using the Kaplan–Meier method for multivariate analysis. The disease-free survival was analyzed using the log-rank test.

### 3. Results

#### 3.1. Basic demographics and clinical nature of local recurrences

The median follow-up period for the 2050 patients was 70 months (range 0.2–232.4 months). A total of 817 patients

Table 3

| Clinicopathologic characteristics of patients with local recurrence according to recurrence site (\( n=147 \)) |
|---------------------------------------------------------------|
| Axial (\( n=59 \)) | Nonaxial (\( n=88 \)) | \( P \) |
|-------------------|---------------------|------|
| Sex, n (%)        |                     |      |
| Female            | 23 (39.0)           | 40 (45.5) | 0.437 |
| Male              | 36 (61.0)           | 48 (54.5) |      |
| Age, y            |                     |      |
| Median, range     | 60 (38–87)          | 56 (22–81) | 0.112 |
| ASA               |                     |      |
| 1–2               | 57 (66.6)           | 86 (97.7) | 1.000 |
| 3–4               | 2 (3.4)             | 2 (2.3) |      |
| Distance from anal verge, cm     |                     |      |
| Median, range     | 6.0 (1.0–14.0)      | 4.5 (1.0–14.0) | 0.004 |
| Initial stage     |                     |      |
| I                 | 4 (6.8)             | 11 (12.5) | 0.195 |
| II                | 13 (22.0)           | 27 (30.7) |      |
| III               | 42 (71.2)           | 50 (56.8) |      |
| Pathologic T stage|                     |      |
| T0                | 0 (0.0)             | 2 (2.3) | 0.830 |
| T1                | 1 (1.7)             | 2 (2.3) |      |
| T2                | 9 (15.3)            | 13 (14.8) |      |
| T3                | 45 (76.3)           | 66 (75.0) |      |
| T4                | 4 (6.8)             | 5 (5.7) |      |
| Pathologic N stage|                     |      |
| N0                | 27 (45.8)           | 35 (39.8) | 0.391 |
| N1                | 18 (30.5)           | 26 (29.5) |      |
| N2                | 14 (23.7)           | 27 (30.7) |      |
| Number of harvested lymph node |             |      |
| <12               | 20 (33.9)           | 36 (40.9) | 0.174 |
| CRM               |                     |      |
| <1 cm             | 7 (11.9)            | 18 (20.5) |      |
| ≥1 cm             | 52 (88.1)           | 70 (79.5) |      |
| CRM               |                     |      |
| Negative          | 31 (52.5)           | 59 (67.0) | 0.177 |
| Positive          | 1 (1.7)             | 2 (2.3) |      |
| Not available     | 27 (45.8)           | 27 (30.7) |      |
| Surgical procedure|                     |      |
| Sphincter-preserving resection | 47 (79.7) | 61 (69.1) | 0.164 |
| Non-sphincter-preserving resection | 12 (20.3) | 27 (30.7) |      |
| Initial CEA, ng/mL |                     |      |
| ≤5                | 25 (42.4)           | 49 (55.7) | 0.260 |
| >5                | 20 (33.9)           | 21 (23.9) |      |
| Not available     | 14 (23.7)           | 18 (20.5) |      |
| Cell type         |                     | 0.320 |
| WD=MD             | 53 (89.8)           | 74 (84.1) |      |
| PD=MUC+SRC        | 6 (10.2)            | 14 (15.9) |      |
| LVI               |                     | 0.482 |
| No                | 14 (23.7)           | 24 (27.3) |      |
| Yes               | 37 (62.7)           | 45 (51.1) |      |
| Not available     | 14 (23.7)           | 18 (20.5) |      |
| NLRadjuvant CCRT  |                     | 0.380 |
| No                | 51 (86.4)           | 67 (76.1) |      |
| Yes               | 8 (13.6)            | 21 (23.9) |      |
| Adjuvant chemotherapy |                 | 0.222 |
| No                | 18 (30.9)           | 19 (21.6) |      |
| Yes               | 41 (69.5)           | 69 (78.4) |      |
| Pattern of metastasis |                   | 0.562 |
| Local only        | 41 (69.5)           | 65 (73.9) |      |
| Combined metastases | 18 (30.5)           | 23 (26.1) |      |

ASA = American Society of Anesthesiologists, CCRT = concurrent chemoradiotherapy, CEA = carcinoembryonic antigen, CRM = circumferential resection margin, DRM = distal resection margin, LVI = lymphovascular invasion, MD = moderately differentiated, MUC = mucinous, N = node, PD = poorly differentiated, PNI = perineural invasion, SRC = signet ring cell, T = tumor, WD = well differentiated.
3.3. Survival analysis after local recurrence

The 1-, 3-, and 5-year overall survival rates of patients after diagnosis of local recurrence were 75.4%, 36.7%, and 19.1%, respectively. Univariate analysis revealed that advanced pathologic tumor stage (P = 0.001); positive nodal status (P = 0.011); ≥ 1 cm distal resection margin (P = 0.048); poorly differentiated, mucinous, or signet ring cell histologic cell type (P = 0.010); positive CRM (P = 0.025); combined distant metastases (P < 0.001); and nonsurgical treatment of locally recurrent rectal cancer (P < 0.001) significantly affected overall survival after local recurrence. However, the site of local recurrence was not associated with prognosis (P = 0.146). Multivariate analysis revealed that advanced pathologic tumor stage (P = 0.040, HR = 1.867, 95% CI = 1.028–3.389), positive CRM (P = 0.001, HR = 12.929, 95% CI = 2.906–57.604), combined distant metastases (P = 0.001, HR = 2.086, 95% CI = 1.352–3.218), and nonsurgical resection of the recurrent tumor (P < 0.001, HR = 4.865, 95% CI = 2.586–9.153) were significant predictors of worse overall survival after local recurrence (Table 6, Fig. 2A). After propensity score matching to correct selection bias for surgical resection of locally recurrent cancer, surgical treatment was associated with significantly better survival (Supplementary Table 1 and Figure 1, http://links.lww.com/MD/B108). However, R0 resection did not

### Table 4

| Local recurrence only (n = 106) | Combined recurrence (n = 41) | P |
|-------------------------------|-------------------------------|---|
| Axial (n = 41) | Nonaxial (n = 65) | CCRT | Axial (n = 18) | Nonaxial (n = 23) | CCRT |
| Surgical resection | 21 (51.2) | 10 (15.4) | 0.001 | 1 (5.6) | 1 (4.3) | 0.620 |
| CCRT | 3 (7.3) | 16 (24.6) | | 0 (0.0) | 2 (8.7) | |
| Radiotherapy only | 2 (4.9) | 2 (3.1) | | 0 (0.0) | 0 (0.0) | |
| Chemotherapy only | 6 (14.6) | 27 (41.5) | | 11 (61.1) | 14 (60.9) | |
| None or conservative management | 9 (22.0) | 10 (15.4) | | 6 (33.3) | 6 (26.1) | |

**CCRT = concurrent chemoradiotherapy.**
Table 6
Univariate and multivariate analyses of prognostic factors affecting overall survival after local recurrence in patients with locally recurrent rectal cancer (n=147).

| Predictor                        | Univariate          | Multivariate       |
|----------------------------------|----------------------|---------------------|
|                                  | Ratio of risk (95% CI) | P     | Ratio of risk (95% CI) | P     |
| Sex                              | 1.081 (0.742–1.577)  | 0.684           |                       |       |
| Female vs male                   | 1.184 (0.783–1.791)  | 0.423           |                       |       |
| Age, y                           | 1.443 (0.988–2.106)  | 0.058           | 1.867 (1.028–3.389)  | 0.040 |
| ASA                              | 2.503 (0.917–6.834)  | 0.073           | 0.984 (0.637–1.519)  | 0.942 |
| pT stage                         | 1.036 (0.709–1.514)  | 0.856           |                       |       |
| T3–4 vs T0–2                     | 2.618 (1.486–4.612)  | 0.001           | 1.621 (0.889–2.955)  | 0.115 |
| pN stage                         | 1.673 (1.125–2.488)  | 0.011           |                       |       |
| No vs ND                         | 1.131 (0.760–1.684)  | 0.544           |                       |       |
| Number of harvested lymph node   | 1.795 (1.004–3.207)  | 0.048           |                       |       |
| Distal resection margin, cm      | 1.184 (0.783–1.791)  | 0.104           |                       |       |
| >5 vs ≤5                         | 1.327 (0.851–2.069)  | 0.010           | 1.682 (1.074–2.219)  | 0.375 |
| Cell type                        | 1.298 (1.179–3.352)  | 0.010           | 1.282 (0.741–2.219)  | 0.375 |
| PD+MUC+SRC vs WD+MD              | 1.686 (0.977–2.909)  | 0.061           |                       |       |
| Positive LVI                     | 1.151 (0.594–2.232)  | 0.678           | 12.939 (2.906–57.604)| 0.001 |
| Positive PNI                     | 1.244 (1.224–21.584)| 0.025           |                       |       |
| Positive CRM                     | 5.141 (1.224–21.584)| 0.254           |                       |       |
| Neadjuvant CCRT                  | 1.343 (0.809–2.277)  | 0.420           |                       |       |
| Adjuvant chemotherapy/CCRT       | 1.209 (0.762–1.920)  | <0.001          |                       |       |
| Yes vs no                        | 2.804 (1.845–4.263)  | 0.146           | 2.086 (1.352–3.218)  | 0.001 |
| Recurrence location              | 1.298 (1.179–3.352)  | 0.010           |                       |       |
| Nonaxial vs axial                | 1.343 (0.903–1.999)  | 0.146           |                       |       |
| Surgical resection (no vs yes)   | 5.680 (3.077–10.485) | <0.001          | 4.865 (2.586–9.153)  | <0.001|

ASA = American Society of Anesthesiologists, CCRT = concurrent chemoradiotherapy, CEA = carcinoembryonic antigen, CRM = circumferential resection margin, LVI = lymphovascular invasion, PNI = perineural invasion, MD = moderately differentiated, MUC = mucinous, N = node, PD = poorly differentiated, SRC = signet ring cell, T = tumor, WD = well differentiated.

4. Discussion

The local recurrence rate of curatively resected rectal cancer in our large database was 5.9%. Surgical resection of locally recurrent rectal cancer significantly increased overall survival after diagnosis of local recurrence, irrespective of R0 resection. Moreover, predictive factors for surgery included less advanced tumor stage (below T3), axial recurrence, and isolated local recurrence. The rates of local recurrence of curatively resected rectal cancer have been reported to vary from 3.7 to 13.0% as the introduction of TME, regardless of whether or not preoperative chemoradiotherapy or radiotherapy are performed. These rates are comparable with our results. We also found that the rate of local recurrence was significantly higher in patients who underwent sphincter-preserving surgery compared with sphincter-preserving surgery (11.9% vs 6.3%, P < 0.001), which is also consistent with other reports. One possible explanation for this finding may be both the anatomical features of the pelvic floor and that tumor cells are pushed into the lateral lymph flow routes during surgery, leaking back into the surgical volume after resection of low rectal cancer. Preoperative CCRT did not lower the local recurrence rate, although it did significantly lower the combined distant and local recurrence rate. Interestingly, synchronous distant metastasis was revealed to significantly worsen overall survival after diagnosis of recurrence. However, preoperative CCRT did not prolong overall survival after either the first surgery or a diagnosis of local recurrence in this analysis. A number of studies in the last few years investigating preoperative CCRT treatment for locally advanced rectal cancer have demonstrated the efficacy of this treatment in complete pathologic response, tumor down-staging, and enhanced sphincter preservation, including local control. However, the impact of preoperative CCRT on overall survival is highly controversial. For example, 1 study found that local recurrence after previous radiotherapy was associated with a significantly shorter survival duration compared with patients with local recurrence who did not receive PRT for the primary tumor. This finding could be due to selection bias for preoperative radiotherapy of patients with unfavorable primary
tumor characteristics and other treatment options after recurrence.

The classification and subsites of local recurrences have been found to vary. The most common site of local recurrence also remains controversial. Prior to the development of total mesorectal excision, the most common local types of recurrence tended to be central (perianastomotic and anterior). Lateral and posterior types (presacral), however, have become more common as combined treatments have come into use. A Dutch group analyzed local recurrence patterns using the same classification system as used in our analysis and found that presacral local recurrence was the most common subtype, especially in patients who underwent abdominoperineal resection. They also found that preoperative radiotherapy reduced local recurrence, especially anastomotic recurrence. In our study, lateral recurrence was the most common, but less anastomotic recurrence was observed in patients with preoperative CCRT, which is consistent with previous findings. Furthermore, presacral recurrence was the second most common subtype (3.4%), following only lateral recurrence (4.6%) in patients who underwent nonsphincter-preserving surgery.

The survival benefit of surgical resection of locally recurrent rectal cancer has been clearly established by several studies. Rahbari et al reported that surgical resection of local recurrence can be carried out with acceptable morbidity and curative resection rates; moreover, R0 resection is a major prognostic factor that may enable long-term survival, even in patients with combined distant recurrence. In the present study, we found that surgery was also a prognostic factor for significantly improved overall survival in patients with rectal cancer, even after a diagnosis of local recurrence, regardless of R0 resection, possibly owing to the small number of patients.

In a recent study performed at our institution, a CRM ≤ 1 mm was an independent predictor of poor outcome in both the nonchemothoradiotherapy and chemoradiotherapy groups. In addition, a positive CRM was associated with a poor survival rate after treatment of local recurrence. Therefore, achieving a negative CRM appears to be very important in the initial primary rectal cancer surgery.

One of the limitations of this study is that R0 resection was not assessed in patients who underwent reoperation for locally recurrent rectal cancer. This study was also limited by its retrospective nature and its potential selection bias. Moreover, preoperative CCRT was performed according to preoperative clinical staging primarily based on radiologic imaging modalities, which may have resulted in over- or undertreatment. An additional limitation is that the effect of pelvic reirradiation could not be assessed, as only a small number of patients underwent radiotherapy for the treatment of locally recurrent rectal cancer. Recent studies have demonstrated the effects of combined treatment modalities with radical surgery. Bosman et al reported that reirradiation (with concomitant chemotherapy) had few side effects and also complemented radical resection of recurrent rectal cancer. Despite these limitations, this study
also presents valuable data such as potential predictive factors for surgical resection and prognosis evaluation after recurrence.

In conclusion, surgical resection of locally recurrent rectal cancer prolongs survival after diagnosis of recurrence, regardless of R0 resection. Thus, such resection should be considered as an initial treatment for locally recurrent rectal cancer. Predictive factors for surgery in patients with local recurrence were found to be less advanced tumor stage (below T3), axial recurrence, and isolated local recurrence. All patients with these factors can be candidates for active surgical management. Also, advanced pathologic tumor stage, positive CRM, and combined distant metastases were significant predictors of worse prognosis after diagnosis of recurrence. Thus, patients diagnosed with local recurrence during follow-up should be carefully examined for distant metastases before curative treatment options such as surgical resection are considered.

References

[1] Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 1982;69:613–6.
[2] Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479–82.
[3] van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575–82.
[4] Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693–701.
[5] Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638–46.
[6] Yu TK, Bhosale PR, Czane CH, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2008;71:1175–80.
[7] Esnaola NF, Cantor SB, Johnson ML, et al. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J Clin Oncol 2002;20:4361–7.
[8] Hertarth C, Schlag P, Hohenberger P. Surgical strategies in locoregional recurrences of gastrointestinal carcinoma. World J Surg 1987;11: 504–10.
[9] Rahbri NN, Ulrich AB, Bruckner T, et al. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? Ann Surg 2011;253:322–33.
[10] Huh JW, Kim YJ, Kim HJ. Distribution of lymph node metastases is an independent predictor of survival for sigmoid colon and rectal cancer. Ann Surg 2012;255:70–8.
[11] Park JS, Huh JW, Park TA, et al. A circumferential resection margin of 1 mm is a negative prognostic factor in rectal cancer patients with and without neoadjuvant chemoradiation. Dis Colon Rectum 2014;57:933–40.
[12] Wells BJ, Stroeland P, Ko MA, et al. Results of an aggressive approach to resection of locally recurrent rectal cancer. Ann Surg Oncol 2007;14:390–5.
[13] Hocht S, Mann B, Germer CT, et al. Pelvic sidewall involvement in recurrent rectal cancer. Int J Colorectal Dis 2004;19:108–13.
[14] Enriquez-Navascues JM, Borda N, Lizerazu A, et al. Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol 2011;17:1674–84.
[15] Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol 2010;36:470–6.
[16] Heald RJ, Moran BJ, Ryall RD, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 1998;133:894–9.
[17] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1751–40.
[18] Kim TH, Jeong SY, Chot DH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol 2008;15:729–37.
[19] Chua AK, Wong A, Jenken D, et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:665–77.
[20] Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26:303–12.
[21] Salerno G, Sinnatamby C, Branagan G, et al. Defining the rectum: surgically, radiologically and anatomically. Colorectal Dis 2006;8(Suppl 3):5–9.
[22] den Dulk M, Marijnen CA, Putter H, et al. Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. Ann Surg 2007;246:83–90.
[23] Kusters M, Holman FA, Marijnen H, et al. Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment. Radiother Oncol 2009;92:221–5.
[24] Wheeler JM, Dodds E, Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 2004;47:2025–31.
[25] Kao PS, Chang SC, Wang LW, et al. The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J Surg Oncol 2010;102:771–7.
[26] Medical Research Council Rectal Cancer Working Party Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996; 348:1605–10.
[27] Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 2000;284:1008–15.
[28] Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124–30.
[29] van den Brink M, Stiggelbout AM, van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 2004;22:3938–44.
[30] Suzuki K, Dozois RR, Devine RM, et al. Curative reoperations for locally recurrent rectal cancer. Dis Colon Rectum 1996;39:730–6.
[31] Wanebo HJ, Antoniuk P, Kones RJ, et al. Pelvic revison of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum 1999;42:1438–48.
[32] Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al. Pucciarelli S. cT3N0 potentially operable locally advanced rectal cancer. Lancet 1996;348:1605–10.
[33] Hertl AK, Tekkis PP, Darzi A, et al. Surgery for local recurrence of colorectal cancer. Colorectal Dis 2006;8(Suppl 3):5–9.
[34] Hahnloser D, Nelson H, Gunderson LL, et al. Pelvic exenteration in the treatment of locally recurrent rectal cancer. Ann Surg Oncol 2005;12:477–85.
[35] Heriot AG, Tekkis PP, Darzi A, et al. Surgery for locoregional failure after preoperative chemoradiation. J Am Coll Surg 2004;209:509–16.
[36] Heriot AG, Tekkis PP, Darzi A, et al. Surgery for local recurrence of rectal carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124–30.
[37] Hahnloser D, Nelson H, Gunderson LL, et al. Pelvic exenteration in the treatment of locally recurrent rectal cancer. Ann Surg Oncol 2005;12:477–85.
[38] Heriot AG, Tekkis PP, Darzi A, et al. Surgery for local recurrence of rectal carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124–30.
[39] Hahnloser D, Nelson H, Gunderson LL, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg Oncol 2008;15:1937–47.
[40] Heriot AG, Byrne CM, Lee P, et al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 2008;51:284–91.
[41] Bosman SJ, Holman FA, Niehuis HJ, et al. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg 2014;101:1280–9.